MedTrace Logo

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

NCT00897247 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 494

Last updated 2014-03-05

No results posted yet for this study

Summary

RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.

Conditions

  • Malignant Mesothelioma
  • Pulmonary Complications

Interventions

GENETIC

microarray analysis

GENETIC

protein expression analysis

GENETIC

proteomic profiling

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Anil Wali, PhD · Barbara Ann Karmanos Cancer Institute

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2013-03-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897247 on ClinicalTrials.gov